132 related articles for article (PubMed ID: 8811498)
1. Hematologic and immunologic evaluation of recombinant human interleukin-6 in patients with advanced malignant disease: evidence for monocyte activation.
Keever-Taylor CA; Witt PL; Truitt RL; Ramanujam S; Borden EC; Ritch PS
J Immunother Emphasis Tumor Immunol; 1996 May; 19(3):231-43. PubMed ID: 8811498
[TBL] [Abstract][Full Text] [Related]
2. Biologic response modulation by tumor necrosis factor alpha (TNF alpha) in a phase Ib trial in cancer patients.
Logan TF; Gooding WE; Whiteside TL; Ernstoff MS; Kaplan SS; Miketic L; Vlock DR; Tompkins C; Wood DL; Nadler PI; Kirkwood JM
J Immunother; 1997 Sep; 20(5):387-98. PubMed ID: 9336746
[TBL] [Abstract][Full Text] [Related]
3. A phase I trial of recombinant human interleukin-6 in patients with myelodysplastic syndromes and thrombocytopenia.
Gordon MS; Nemunaitis J; Hoffman R; Paquette RL; Rosenfeld C; Manfreda S; Isaacs R; Nimer SD
Blood; 1995 Jun; 85(11):3066-76. PubMed ID: 7538815
[TBL] [Abstract][Full Text] [Related]
4. Immunomodulatory and hematopoietic effects of recombinant human interleukin-6 in patients with advanced renal cell cancer.
Schuler M; Peschel C; Schneller F; Fichtner J; Färber L; Huber C; Aulitzky WE
J Interferon Cytokine Res; 1996 Nov; 16(11):903-10. PubMed ID: 8938565
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
6. Phase 1 trial of subcutaneous IL-6 in patients with refractory cancer: clinical and biologic effects.
Olencki T; Finke J; Tubbs R; Elson P; McLain D; Herzog P; Budd GT; Gunn H; Bukowski RM
J Immunother; 2000; 23(5):549-56. PubMed ID: 11001548
[TBL] [Abstract][Full Text] [Related]
7. Thrombopoietic effects and toxicity of interleukin-6 in patients with ovarian cancer before and after chemotherapy: a multicentric placebo-controlled, randomized phase Ib study.
D'Hondt V; Humblet Y; Guillaume T; Baatout S; Chatelain C; Berlière M; Longueville J; Feyens AM; de Greve J; Van Oosterom A
Blood; 1995 May; 85(9):2347-53. PubMed ID: 7537110
[TBL] [Abstract][Full Text] [Related]
8. Biologic activity of interleukin 1 (IL-1) alpha in patients with refractory malignancies.
Rosenthal MA; Dennis D; Liebes L; Furmanski P; Caron D; Garrison L; Wiprovnick J; Peace D; Oratz R; Speyer J; Chachoua A
J Immunother; 1998 Sep; 21(5):371-8. PubMed ID: 9789199
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies.
Weber J; Yang JC; Topalian SL; Parkinson DR; Schwartzentruber DS; Ettinghausen SE; Gunn H; Mixon A; Kim H; Cole D
J Clin Oncol; 1993 Mar; 11(3):499-506. PubMed ID: 7680375
[TBL] [Abstract][Full Text] [Related]
10. Activation of the immune system of cancer patients by continuous i.v. recombinant IL-2 (rIL-2) therapy is dependent on dose and schedule of rIL-2.
Gratama JW; Bruin RJ; Lamers CH; Oosterom R; Braakman E; Stoter G; Bolhuis RL
Clin Exp Immunol; 1993 May; 92(2):185-93. PubMed ID: 8485906
[TBL] [Abstract][Full Text] [Related]
11. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer.
Conlon KC; Lugli E; Welles HC; Rosenberg SA; Fojo AT; Morris JC; Fleisher TA; Dubois SP; Perera LP; Stewart DM; Goldman CK; Bryant BR; Decker JM; Chen J; Worthy TA; Figg WD; Peer CJ; Sneller MC; Lane HC; Yovandich JL; Creekmore SP; Roederer M; Waldmann TA
J Clin Oncol; 2015 Jan; 33(1):74-82. PubMed ID: 25403209
[TBL] [Abstract][Full Text] [Related]
12. Immunopharmacology and cytokine production of a low-dose schedule of intraperitoneally administered human recombinant interleukin-2 in patients with advanced epithelial ovarian carcinoma.
Freedman RS; Gibbons JA; Giedlin M; Kudelka AP; Kavanagh JJ; Edwards CL; Carrasco CH; Nash MA; Platsoucas CD
J Immunother Emphasis Tumor Immunol; 1996 Nov; 19(6):443-51. PubMed ID: 9041464
[TBL] [Abstract][Full Text] [Related]
13. Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response.
Fehniger TA; Shah MH; Turner MJ; VanDeusen JB; Whitman SP; Cooper MA; Suzuki K; Wechser M; Goodsaid F; Caligiuri MA
J Immunol; 1999 Apr; 162(8):4511-20. PubMed ID: 10201989
[TBL] [Abstract][Full Text] [Related]
14. Interferon-gamma, interleukin-4 and transforming growth factor-beta mRNA expression in multiple sclerosis and myasthenia gravis.
Link J
Acta Neurol Scand Suppl; 1994; 158():1-58. PubMed ID: 7732782
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of subcutaneous recombinant macrophage colony-stimulating factor: clinical and immunomodulatory effects.
Bukowski RM; Budd GT; Gibbons JA; Bauer RJ; Childs A; Antal J; Finke J; Tuason L; Lorenzi V; McLain D
J Clin Oncol; 1994 Jan; 12(1):97-106. PubMed ID: 8270990
[TBL] [Abstract][Full Text] [Related]
16. Eosinophils activation in post-autologous bone marrow transplanted patients treated with subcutaneous interleukin-2 and interferon-alpha 2A immunotherapy.
Fabian I; Kravtsov V; Elis A; Gurevitch O; Ackerstein A; Slavin S; Nagler A
Leukemia; 1994 Aug; 8(8):1379-84. PubMed ID: 8057677
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors.
Conlon K; Watson DC; Waldmann TA; Valentin A; Bergamaschi C; Felber BK; Peer CJ; Figg WD; Potter EL; Roederer M; McNeel DG; Thompson JA; Gupta S; Leidner R; Wang-Gillam A; Parikh NS; Long D; Kurtulus S; Ho Lee L; Chowdhury NR; Bender F; Pavlakis GN
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34799399
[TBL] [Abstract][Full Text] [Related]
18. Expansion of peripheral blood natural killer cells correlates with clinical outcome in cancer patients receiving recombinant subcutaneous interleukin-2 and interferon-alpha-2.
Atzpodien J; Kirchner H; Körfer A; Hadam M; Schomburg A; Menzel T; Deckert M; Franzke A; Volkenandt M; Dallmann I
Tumour Biol; 1993; 14(6):354-9. PubMed ID: 8265981
[TBL] [Abstract][Full Text] [Related]
19. Independent expression of p55 and p75 interleukin-2 receptors (IL-2R) during intravenous or subcutaneous administration of recombinant interleukin-2 (rIL-2) by T-lymphocytes and natural killer cells.
Zambello R; Trentin L; Cerutti A; Enthammer C; Milani A; Franceschi T; Messina C; Cetto GL; Agostini C; Semenzato G
Cancer; 1994 Nov; 74(9):2562-9. PubMed ID: 7522954
[TBL] [Abstract][Full Text] [Related]
20. Cytokine serum levels during treatment with high-dose recombinant human IL-3 in a patient with severe aplastic anemia.
Nachbaur D; Gratwohl A; Herold M; Tichelli A; Slanicka M; Nissen C; Niederwieser D; Speck B
Ann Hematol; 1993 Feb; 66(2):71-5. PubMed ID: 8448242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]